Statement of Ownership (sc 13g)
November 22 2019 - 11:43AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
SCHEDULE
13G
Under
the Securities Exchange Act of 1934
*
OncoCyte
Corporation
(Name
of Issuer)
Common
Stock, No Par Value
(Title
of Class of Securities)
68235C107
(CUSIP
Number)
November
13, 2019
(Date
of Event Which Requires Filing of this Statement)
Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:
[ ]
Rule 13d-1(b)
[X]
Rule 13d-1(c)
[ ]
Rule 13d-1(d)
*The
remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the
subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided
in a prior cover page.
The
information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes).
1.
|
NAME
OF REPORTING PERSONS
I.R.S.
IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Pura
Vida Investments LLC
|
2.
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a)
[ ]
(b) [X]
|
3.
|
SEC USE ONLY
|
4.
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
Delaware
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED
BY
EACH
REPORTING
PERSON
WITH
|
5.
|
SOLE
VOTING POWER
0
|
6.
|
SHARED
VOTING POWER
2,941,176
|
7.
|
SOLE
DISPOSITIVE POWER
0
|
8.
|
SHARED
DISPOSITIVE POWER
2,941,176
|
9.
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,941,176
|
10.
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
[ ]
|
11.
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.16%
|
12.
|
TYPE
OF REPORTING PERSON (SEE INSTRUCTIONS)
IA
|
1.
|
NAME
OF REPORTING PERSONS
I.R.S.
IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Efrem
Kamen
|
2.
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a)
[ ]
(b) [X]
|
3.
|
SEC USE ONLY
|
4.
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
United
States of America
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED
BY
EACH
REPORTING
PERSON
WITH
|
5.
|
SOLE
VOTING POWER
0
|
6.
|
SHARED
VOTING POWER
2,941,176
|
7.
|
SOLE
DISPOSITIVE POWER
0
|
8.
|
SHARED
DISPOSITIVE POWER
2,941,176
|
9.
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,941,176
|
10.
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
[ ]
|
11.
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.16%
|
12.
|
TYPE
OF REPORTING PERSON (SEE INSTRUCTIONS)
IN,
HC
|
Item
1.
|
(a).
|
Name
of Issuer:
|
|
|
|
|
|
OncoCyte
Corporation
|
|
|
|
|
(b).
|
Address
of issuer’s principal executive offices:
|
|
|
|
|
|
1010
Atlantic Avenue, Suite 102
|
|
|
Alameda,
CA 94501
|
|
|
|
Item
2.
|
(a).
|
Name
of person filing:
|
|
|
|
|
|
Pura
Vida Investments LLC
|
|
|
Efrem
Kamen
|
|
|
|
|
(b).
|
Address
or principal business office or, if none, residence:
|
|
|
|
|
|
Pura
Vida Investments LLC
|
|
|
150
East 52nd Street Suite 32001
|
|
|
New
York, New York 10022
|
|
|
|
|
|
Efrem
Kamen
|
|
|
c/o
Pura Vida Investments LLC
|
|
|
150
East 52nd Street Suite 32001
|
|
|
New
York, New York 10022
|
|
|
|
|
(c).
|
Citizenship:
|
|
|
|
|
|
Pura
Vida Investments LLC – Delaware limited liability company
|
|
|
Efrem
Kamen – United States of America
|
|
|
|
|
(d)
|
Title
of class of securities:
|
|
|
|
|
|
Common
Stock, No Par Value
|
|
|
|
|
|
CUSIP
No.:
|
|
|
|
|
(e).
|
68235C107
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Item
3.
|
If
This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is
a
|
|
(a)
|
|
[_]
|
|
Broker
or dealer registered under section 15 of the Act (15 U.S.C. 78o).
|
|
|
|
|
|
|
|
(b)
|
|
[_]
|
|
Bank
as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
|
|
|
|
|
|
|
|
(c)
|
|
[_]
|
|
Insurance
company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
|
|
|
|
|
|
|
|
(d)
|
|
[_]
|
|
Investment
company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
|
|
|
|
|
|
|
|
(e)
|
|
[_]
|
|
An
investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
|
|
|
|
|
|
|
|
(f)
|
|
[_]
|
|
An
employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
|
|
|
|
|
|
|
|
(g)
|
|
[_]
|
|
A
parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
|
|
|
|
|
|
|
|
(h)
|
|
[_]
|
|
A
savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
|
|
|
|
|
|
|
|
(i)
|
|
[_]
|
|
A
church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company
Act of 1940 (15 U.S.C. 80a-3);
|
|
|
|
|
|
|
|
(j)
|
|
[_]
|
|
A
non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
|
|
|
|
|
|
|
|
(k)
|
|
[_]
|
|
Group,
in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
|
Provide
the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in
Item 1.
|
(a)
|
Amount
beneficially owned:
|
|
|
Pura
Vida Investments LLC – 2,941,176 shares
|
|
|
Efrem
Kamen – 2,941,176 shares
|
|
|
Pura
Vida Investments LLC – 5.16%*
|
|
|
Efrem
Kamen – 5.16%*
|
|
(c)
|
Number
of shares as to which Pura Vida Investments LLC has:
|
|
(i)
|
Sole
power to vote or to direct the vote
|
|
0
|
,
|
|
|
|
|
|
|
|
(ii)
|
Shared
power to vote or to direct the vote
|
|
2,941,176
|
,
|
|
|
|
|
|
|
|
(iii)
|
Sole
power to dispose or to direct the disposition of
|
|
0
|
,
|
|
|
|
|
|
|
|
(iv)
|
Shared
power to dispose or to direct the disposition of
|
|
2,941,176
|
.
|
|
|
|
|
|
|
|
Number
of shares as to which Efrem Kamen has:
|
|
|
|
|
|
|
|
|
|
|
(i)
|
Sole
power to vote or to direct the vote
|
|
0
|
,
|
|
|
|
|
|
|
|
(ii)
|
Shared
power to vote or to direct the vote
|
|
2,941,176
|
,
|
|
|
|
|
|
|
|
(iii)
|
Sole
power to dispose or to direct the disposition of
|
|
0
|
,
|
|
|
|
|
|
|
|
(iv)
|
Shared
power to dispose or to direct the disposition of
|
|
2,941,176
|
.
|
*Shares
reported herein are held by Pura Vida Master Fund, Ltd. (the “Pura Vida Master Fund”), and certain separately managed
accounts (the “Accounts”). Pura Vida Investments LLC (“PVI”) serves as the investment manager to the Pura
Vida Master Fund and the Accounts. Efrem Kamen serves as the managing member of PVI.
By
virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to
the Shares owned directly by the Pura Vida Master Fund and the Accounts. This report shall not be deemed an admission that the
Reporting Persons are beneficial owners of the Shares for purposes of Section 13 of the Securities Exchange Act of 1934, as amended,
or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to
the extent of the Reporting Person’s pecuniary interest therein.
The
percentages herein are calculated based upon a statement in the Issuer’s Quarterly Report on Form 10-Q filed on November
14, 2019 for the quarter ended September 30, 2019 that (i) there were 51,972,830 shares of Common Stock issued and outstanding
as of October 29, 2019, plus (ii) 5,058,824 shares of Common Stock that the Issuer agreed to sell as part of a stock purchase
agreement, expected to close on November 15, 2019, totaling 57,031,654 shares of Common Stock.
Item
5.
|
Ownership
of Five Percent or Less of a Class.
|
|
If
this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial
owner of more than five percent of the class of securities, check the following [ ].
|
|
|
|
N/A
|
Item
6.
|
Ownership
of More Than Five Percent on Behalf of Another Person.
|
|
If
any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds
from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest
relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment
company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or
endowment fund is not required.
|
|
|
|
N/A
|
Item
7.
|
Identification
and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control
Person.
|
|
If
a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under
Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent
holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating
the identification of the relevant subsidiary.
|
|
|
|
N/A
|
Item
8.
|
Identification
and Classification of Members of the Group.
|
|
If
a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit
stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to
Rule 13d- 1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.
|
|
|
|
N/A
|
Item
9.
|
Notice
of Dissolution of Group.
|
|
Notice
of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings
with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual
capacity. See Item 5.
|
|
|
|
N/A
|
By
signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than
activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
Dated:
November 22, 2019
|
Pura
Vida Investments LLC
|
|
|
|
|
By:
|
/s/
Efrem Kamen
|
|
Name:
|
Efrem
Kamen
|
|
Title:
|
Managing
Member
|
|
|
|
|
/s/
Efrem Kamen
|
|
Efrem
Kamen
|
The
original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If
the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner
of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the
statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated
by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.
Note.
Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7
for other parties for whom copies are to be sent.
Attention.
Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).
OncoCyte (AMEX:OCX)
Historical Stock Chart
From Aug 2024 to Sep 2024
OncoCyte (AMEX:OCX)
Historical Stock Chart
From Sep 2023 to Sep 2024